RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radiopharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radiolabeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.
RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.
RadioMedix offers unique products and services for Nuclear Medicine researchers and clinicians. Our products are SmartMedix System and GlucoMedix. We also provide services such as cGMP Drug Manufacturing Suite and Micro-PET Laboratory Services.More >>